blank
blank
On 13 November in Milan, EMA’s expert committee backs Italy’s first home‑grown gene therapy for people in Europe living with Wiskott–Aldrich Syndrome.

First Italian-made gene therapy for Wiskott-Aldrich Syndrome

European Medicines Agency (EMA)

On 13 November, the European Medicines Agency (EMA) announced the Committee for Medicinal Products for Human Use (CHMP) positive opinion recommending marketing authorisation for Etuvetidigene autotemcel (Waskyra®). This is an ex vivo hematopoietic stem cell gene therapy intended to treat adults and children aged older than 6 months with Wiskott-Aldrich syndrome (WAS), a rare and life-threatening immunodeficiency. The therapy reduces the frequency of bleeding events and serious infections in patients, especially in cases where transplantation from a compatible family donor is not possible.

Waskyra® is the result of decades of research at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) and of a clinical development program conducted at IRCCS Ospedale San Raffaele in Milan, Italy. Data obtained from this program demonstrated a significant reduction in the annualised rate of severe health events following the treatment.

Waskyra® was supported through an “EMA pilot” program, which offers enhanced support to academic and non-profit developers of ATMPs addressing unmet medical needs.

This milestone highlights the growing impact of ATMPs in changing the lives of people with WAS in the EU, providing them with new hope.

Importantly, the applicant of the marketing authorisation is Fondazione Telethon ETS, the first non-profit marketing authorization holder in the European Union. In fact, in 2023, they obtained the marketing authorization holder of another advanced therapy for an ultra-rare disease, adenosine deaminase severe combined immunodeficiency (ADA-SCID).

Next steps include the European Commission final marketing authorisation to make it available for EU WAS patients. The gene therapy is also under review for authorisation to market by the U.S. Food and Drug Administration (FDA). You can read more information by following these links:

News & Updates

You might also be interested in

stocksnap-people-2574170_1920

EMA launches consultation on proof-of-concept data in paediatric oncology

This initiative is also highly relevant from a rare diseases perspective, as paediatric cancers are rare conditions where small patient populations make robust non‑clinical proof‑of‑concept data essential for responsible and ethical trial initiation.
kitt_ks-lab-2107514_1920

Towards animal-free testing: virtual control groups gain regulatory acceptance

For rare diseases, where research often relies on limited animal models and small development teams, the regulatory acceptance of virtual control groups could help streamline early non‑clinical studies while maintaining a strong focus on patient safety.
P.Sudara - Undiagnosed Day 2026

In Gdańsk, Undiagnosed Day showed why diagnosis is both a scientific and a human challenge

Bringing clinicians, researchers, patient representatives and families together, the event examined how shorter diagnostic pathways depend not only on better tests, but on shared expertise, structured phenotyping and patient-centred support.
ERDERA and european genomic data infrastructure

Strategic collaboration between GDI and ERDERA

ERDERA and the European Genomic Data Infrastructure have signed a Memorandum of Understanding to strengthen collaboration on secure cross-border access to genomic, clinical and other health-related data, supporting rare disease research and the development of personalised medicine in Europe.

ERDERA's

search form